Intravenous thrombolysis in acute myocardial infarction

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 253S-277S

  Ohman, E M ^a   Harrington, R A ^a   Cannon, C P ^a   Agnelli, G ^a   Cairns, J A ^a   Kennedy, J W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; EFEGATRAN; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LANOTEPLASE; LEPIRUDIN; PROUROKINASE; RETEPLASE; SARUPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035130113     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.253S     Document Type: Conference Paper

References (194)

1. Treatment of patients suffering from early, myocardial infarction with massive and prolonged streptokinase therapy
2. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials
3. Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase
4. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction
5. Global and regional left ventricular function and tomographic radionuclide perfusion: The Western Washington intracoronary streptokinase in myocardial infarction trial
6. Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction
7. Overview of results of randomized clinical trials in heart disease: 1. Treatments after myocardial infarction
8. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
11. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
12. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
13. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
14. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli
15. Third-generation thrombolytic agents for acute myocardial infarction
16. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial
17. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction
18. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
19. A faster-acting and more potent form of tissue plasminogen activator
20. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
21. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction
22. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
23. "Plasminogen steal" and clot lysis
24. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
25. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of > 1000 patients
26. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction
27. Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
28. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study
29. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo-controlled trial
30. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction
31. Intracoronary streptokinase, OK!...Intravenous streptokinase first? Heparin or intravenous streptokinase in acute infarction: Preliminary results of a prospective randomized trial with angiographic evaluation in 44 patients
32. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction (ECSG-1)
33. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty
34. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction
35. Effectiveness of intravenous streptokinase on infarct size and left ventricular function in acute myocardial infarction
36. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Effects on infarct size and left ventricular function
37. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction
38. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial
39. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty
40. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction
41. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator
42. Effects of early high-dose streptokinase intravenously on left ventricular function in acute myocardial infarction
43. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction
44. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction
45. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction (ECSG-2)
46. Coronary reperfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase
47. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in myocardial infarction: A randomized multicenter study
48. Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction
49. Etude europeenne multicentrique et randomisee de l'APSAC versus streptokinase dans l'infarctus du myocarde
50. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction
51. A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction
52. Intravenous thrombolytic treatment for acute myocardial infarction: Effects of early intervention and early examination
53. A randomized trial of direct PTCA vs intravenous streptokinase in acute myocardial infarction
54. Plasminogen Activator Italian Multicenter Study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction
55. A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction
56. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction
57. High dose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial
58. High-dose, brief intravenous streptokinase early in acute myocardial infarction
59. Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction
60. High-dose intravenous thrombolytic therapy in acute myocardial infarction: Efficiency, tolerance, complications and influence on left ventricular performance
61. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results oft multicenter randomized trial of two dosage regimens
62. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction
63. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction
64. Immediate versus delayed catheterization and angioplasty after thrombolytic therapy for acute myocardial infarction
65. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction
66. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: Results of thrombolysis and angioplasty in myocardial infarction phase 5 randomized trial
67. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction: A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator
68. Catheterization/Rescue Angioplasty After Thrombolysis (CRAFT) study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase
69. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
70. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator
71. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German activator urokinase study (GAUS)
72. Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity and 1-day coronary, artery patency
73. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infraction (TIMI) phase II trial
74. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial
75. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction
76. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator
77. Link between the angiographic substudy and mortally outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
78. TIM frame count: A quantitative method of assessing coronary artery flow
79. Reduction of infarct size following coronary occlusion
80. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis
81. ST-segment mapping realistic and unrealistic expectations
82. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction
83. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens
84. Resolution of ST segment elevation is an early predictor of mortality in patients with acute myocardial infarction meta analysis of three thrombolysis trials
85. Resolution of ST-segment elevation 90 minutes after thrombolysis for acute myocardial infarction predicts outcome: A GUSTO-substudy
86. Comparison of a 60-versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction
87. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
88. Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitonng in the GUSTO-I trial
89. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients
90. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis In Myocardial Infarction study: Thrombolysis In Myocardial Infarction, phase II; pilot and clinical trial
91. Ischemic stroke and intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
92. The impact of age on the incidence and prognosis of initial acute myocardial infarction: The Worcester Heart Attack Study
93. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: Participants in the National Registry of Myocardial Infarction 2
94. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial
95. An overview of the effect of intravenous heparin on clinical endpoints after thrombolytic therapy for acute myocardial infarction
96. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days
97. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction
98. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction
99. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology
100. Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings
101. Thrombolytic therapy for acute myocardial infarction: A review
102. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
103. Improved thrombolysis in acute myocardial infarction with frontloaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
104. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
105. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
106. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
107. GUSTO, TIMI, and the case for rapid reperfusion
108. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
109. An analysis of the cause of early mortality after administration of thrombolytic therapy
110. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: Strategies for Patency Enhancement in the Emergency Department (SPEED) Group
111. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
112. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction
113. An angiographic assessment of alteplase: Double-bolus and front-loaded infusion regimens in myocardial infarction
114. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
115. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
116. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction: Results of the TIMI IIIB trial
117. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction
118. Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the National Registry of Myocardial Infarction 2+3
119. Cost-minimization analysis of direct injection and infusion fibrinolytic therapy in acute myocardial infarction: A multicenter study
120. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction
121. Prehospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage and Intervention Trial
122. Halving of mortally at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)
123. Relationship between medication errors and adverse drug events
124. Incidence of adverse drug events and potential adverse drug events: Implications for prevention
125. The costs of adverse drug events in hospitalized patients
126. North American vs Non-North American streptokinase use in GUSTO-I: Impact of protocol deviation on mortality benefit of TPA
127. Highlights from the American College of Cardiology 48th Annual Scientific Sessions, March 7 to 10, 1999
128. Patency trials with reteplase (r-PA): What do they tell us?
129. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
130. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
131. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
132. A comparison of reteplase with alteplase for acute myocardial infarction
133. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT- 1 trial
134. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the Thrombolysis In Myocardial Infarction 10B trial
135. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage results from TIMI 10B and ASSENT I
136. Rates of serious bleeding events requiring transfusion in AMpatients treated with TNK-tPA
137. Equivalence trials
138. Timely thrombolysis: Synergism to open arteries and reduce mortality
139. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens
140. Comparison of intracranial hemmorrhage rates in patients treated with rt-PA and TNK-tPA: Impact of gender, age and low body weight
141. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
142. Intravenous urokinase in acute myocardial infarction
143. Results of high dose intravenous urokinase for acute myocardial infarction
144. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction
145. Comparison of saruplase and alteplase in acute myocardial infarction: SESAM Study Group; the Study in Europe with Saruplase and Alteplase in Myocardial Infarction
146. Randomized, double-blind study comparing sarupase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial
147. Thrombolytic therapy and equivalence trials
148. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
149. Intravenous NPA for the treatment of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction
150. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
151. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
152. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS)
153. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage
154. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction
155. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
156. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
157. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
158. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition In Myocardial Infarction (TIMI) 9A trial
159. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
160. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin in Myocardial Infarction (TIMI) 9B trial
161. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
162. Risk of intracranial hemorrhage with accelerated tPA: Importance of the heparin dose
163. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
164. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer
165. Heparin and the activated partial thromboplastin time: A difference between the in-vitro and in-vivo effects and implications for the therapeutic range
166. Inability of the activated partial thromboplastin time to predict heparin levels: Time to reassess guidelines for heparin assays
167. Establishing a therapeutic range for heparin therapy
168. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays
169. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy
170. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
171. Hirudin and derivatives as anticoagulant agents
172. The structure of a complex of recombinant hirudin and human-thrombin
173. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
174. Kinetics of the inhibition of thrombin by hirudin
175. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: A randomised trial
176. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
177. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
178. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
179. A randomized, blinded study of two doses of Novastan (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan and T-PA (MINT) study
180. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction
181. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: A double-blind, randomized, dose-finding study
182. Biology of recombinant hirudin (CGP 39393): A new prospect in the treatment of thrombosis
183. Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty
184. Initial experienee with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial
185. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb trial
186. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK)
187. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial
188. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
189. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
190. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab after thrombolytic therapy: Results of the TAMI 8 pilot study
191. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
192. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and reperfusion Gain in Myocardial infarction (PARADIGM) trial
193. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence